Table 1 Patients characteristics

From: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

 

Level 1, n =3

Level 2, n =29

 

L-OHP (100 mg m−2)

L-OHP (130 mg m−2)

Characteristic

No. of patients (%)

No. of patients (%)

Age (years)

 Median

57

57

 Range

47–60

34–71

Sex

 Male

3 (100)

20 (69)

 Female

0

9 (31)

ECOG performance status

 0

3 (100)

26 (90)

 1

0

3 (10)

Primary tumour

 Colon

2 (67)

18 (62)

 Rectum

1 (33)

11 (38)

Metastatic site

 Liver only

1 (33)

10 (35)

 Lung

0

3 (10)

 Liver and other lesions

1 (33)

10 (35)

 Others

1 (33)

6 (21)

No. of metastatic sites

 1

1 (33)

15 (52)

2

2 (67)

14 (48)

Previous treatment

 Resection

2 (67)

25 (86)

 Adjuvant 5-FU

0

4 (14)

  1. ECOG=Eastern Cooperative Oncology Group; L-OHP=oxaliplatin.